Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belimumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Acronyms BASE
  • Sponsors GlaxoSmithKline; GSK; Human Genome Sciences

    • Most Recent Events

    • 15 Nov 2023 Results assessing the incidence of infections onbelimumab treatment summarized 52-week infection data from BASE study and BEL116559 which is a pooled post hoc analysis of six studies (BEL110751, BEL110752, BEL112341, BEL113750, BEL115471 and LBSL02) presented at the ACR Convergence 2023.
    • 15 Nov 2023 Results assessing of 5-year safety of belimumab therapy in patients with Systemic Lupus Erythematosus, presented at the ACR Convergence 2023.
    • 24 Nov 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top